- Home
- MSB vs ANNX Comparison
MSB vs ANNX Comparison
Compare MSB & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- ANNX
- Stock Information
- Founded
- MSB 1961
- ANNX 2011
- Country
- MSB United States
- ANNX United States
- Employees
- MSB N/A
- ANNX N/A
- Industry
- MSB Metal Mining
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- ANNX Health Care
- Exchange
- MSB Nasdaq
- ANNX Nasdaq
- Market Cap
- MSB 320.9M
- ANNX 334.1M
- IPO Year
- MSB N/A
- ANNX 2020
- Fundamental
- Price
- MSB $30.55
- ANNX $4.44
- Analyst Decision
- MSB
- ANNX Strong Buy
- Analyst Count
- MSB 0
- ANNX 4
- Target Price
- MSB N/A
- ANNX $16.50
- AVG Volume (30 Days)
- MSB 34.9K
- ANNX 3.2M
- Earning Date
- MSB 01-01-0001
- ANNX 11-10-2025
- Dividend Yield
- MSB 22.85%
- ANNX N/A
- EPS Growth
- MSB 425.34
- ANNX N/A
- EPS
- MSB 7.07
- ANNX N/A
- Revenue
- MSB $25,011,439.00
- ANNX N/A
- Revenue This Year
- MSB N/A
- ANNX N/A
- Revenue Next Year
- MSB N/A
- ANNX N/A
- P/E Ratio
- MSB $4.54
- ANNX N/A
- Revenue Growth
- MSB 4.81
- ANNX N/A
- 52 Week Low
- MSB $22.55
- ANNX $1.29
- 52 Week High
- MSB $37.00
- ANNX $5.66
- Technical
- Relative Strength Index (RSI)
- MSB 37.92
- ANNX 72.93
- Support Level
- MSB $33.70
- ANNX $4.17
- Resistance Level
- MSB $35.85
- ANNX $4.70
- Average True Range (ATR)
- MSB 1.86
- ANNX 0.33
- MACD
- MSB -0.58
- ANNX 0.18
- Stochastic Oscillator
- MSB 14.93
- ANNX 76.09
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.